Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for GVHD and Graft Failure Prevention in Haplo-Cord Transplant
NCT04395222Phase 2Active, not recruiting
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2020
- Primary completion
- Sep 2022
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label trial of tocilizumab in graft-versus-host disease (GVHD) and Graft failure, sponsored by Weill Cornell Medicine. Started Oct 2020; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
graft-versus-host disease (GVHD)Graft failure
Beyond the preview
Go deeper on NCT04395222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04395222.